Day L

Avobenzone Octisalate Octinoxate


Kamins Dermatologics Inc.
Human Otc Drug
NDC 63550-122
Day L also known as Avobenzone Octisalate Octinoxate is a human otc drug labeled by 'Kamins Dermatologics Inc.'. National Drug Code (NDC) number for Day L is 63550-122. This drug is available in dosage form of Lotion. The names of the active, medicinal ingredients in Day L drug includes Avobenzone - 25 mg/mL Octinoxate - 75 mg/mL Octisalate - 40 mg/mL . The currest status of Day L drug is Active.

Drug Information:

Drug NDC: 63550-122
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Day L
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Avobenzone Octisalate Octinoxate
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Kamins Dermatologics Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Lotion
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:AVOBENZONE - 25 mg/mL
OCTINOXATE - 75 mg/mL
OCTISALATE - 40 mg/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 01 Mar, 2004
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 18 Jun, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part352
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Kamins Dermatologics Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:G63QQF2NOX
4Y5P7MUD51
4X49Y0596W
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
63550-122-0350 mL in 1 BOX (63550-122-03)01 Mar, 2004N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose: sunscreen

Product Elements:

Day l avobenzone octisalate octinoxate caprylyl glycol sorbic acid water acer saccharum sap butylene glycol hydrolyzed elastin, bovine, alkaline (1000 mw) octocrylene cetyl alcohol glyceryl monostearate ceteareth-12 cyclomethicone 4 cyclomethicone 5 polyethylene glycol 1000 dimethicone coco-caprylate polysorbate 80 carbomer 934 alpha-tocopherol acetate vitamin a palmitate sodium hydroxide phenoxyethanol avobenzone avobenzone octinoxate octinoxate octisalate octisalate

Indications and Usage:

A light, silky lotion that diffuses a blend of moisturizers, anti-oxydant votmins into the skin to enhance day long comfort and hydration. the skin's outer layers are covered with a protective shield, producing a healthy, luminescent glow. uses ■ helps prevent sunburn. ■ higher spf gives more sunburn protection. ■ provides moderate protection against sunburn.

Warnings:

Warnings for external use only. when using this product, keep out of eyes. if contact occurs, rinse abundantly with water to remove. stop use and ask a doctor if rash or irritation develops and lasts. if swallowed, seek medical assistance or contact a poison control center immediately.

Dosage and Administration:

Directions: apply liberally and evenly each morning to cleansed face and neck, before sun exposure and as needed. children under 6 months of age: ask a doctor.

Package Label Principal Display Panel:

B. kamins day lotion spf15 50ml / 1.7 fl.oz din 02248016 day lotion front panel image


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.